Of 45 Russian patients with late complement component deficiency (LCCD) who experienced one to five meningococcal infections, 31 were immunised with a meningococcal A/C/W135/Y polysaccharide vaccine and were followed for 3-8 years. Total and immunoglobulin (Ig) class specific concentration of antibodies to meningococcal polysaccharides in sera of LCCD patients increased significantly 1 month after vaccination and remained elevated for 3 years. Revaccination of LCCD patients 3 years after the first dose restored the total Ig concentrations to those observed 1 year after the first vaccination. Six new episodes of meningococcal infection in four patients developed in the group of 31 vaccinees; six episodes in six patients developed in the same time in the group of 14 non-vaccinated LCCD persons. Survival analysis demonstrated the risk to contract meningococcal disease decreased significantly for vaccinees in comparison to non-vaccinees (P<0.05). Vaccination with of meningococcal tetravalent polysaccharide vaccine decreases the risk of meningococcal infection in LCCD patients.
Bibliographical noteFunding Information:
We thank National Public Health Institute, Finland, and SmithKline Beecham Biologicals, Belgium, for the donation of capsular polysaccharide vaccine. We are thankful for Dr. Cees Fijen, Dr. Ann Orren, Professor Peter Densen, Professor Anders Sjoholm for helpful and inspiring discussions of this project, for Mrs. Sirkka-Liisa Wahlman, Mrs. Kaisa Jousimies, Mrs. Ludmila Kulagina, Mrs. Valentina Ivanova, Mrs. Galina Kovtun and Linda Mahkonen, MD for skilful technical assistance. This study was supported in a part by the grants from the International Association for the Promotion of Cooperation with Scientists from the Independent States of the Former Soviet Union (INTAS), contracts 1010-CT93-0011 and INTAS-OPEN-97–108, and by NATO linkage grant number 975119.
- Complement deficiency
- Meningococcal vaccine